Bupivacaine/epinephrine/dexamethasone (DrugBank: Bupivacaine, Epinephrine, Dexamethasone)
25 diseasesID | Disease name (Link within this page) | Number of trials |
---|---|---|
13 | Multiple sclerosis/Neuromyelitis optica | 0 |
14 | Chronic inflammatory demyelinating polyneuropathy | 0 |
16 | Crow-Fukase syndrome | 0 |
28 | Systemic amyloidosis | 0 |
35 | Pemphigus | 0 |
46 | Malignant rheumatoid arthritis | 0 |
53 | Sjogren syndrome | 0 |
63 | Idiopathic thrombocytopenic purpura | 0 |
64 | Thrombotic thrombocytopenic purpura | 0 |
65 | Primary immunodeficiency | 0 |
70 | Spinal stenosis | 0 |
74 | Prolactin secreting pituitary adenoma | 0 |
75 | Cushing disease | 0 |
81 | Congenital adrenal hyperplasia | 0 |
83 | Addison disease | 0 |
84 | Sarcoidosis | 0 |
90 | Retinitis pigmentosa | 0 |
96 | Crohn disease | 1 |
97 | Ulcerative colitis | 0 |
162 | Pemphigoid | 0 |
222 | Primary nephrotic syndrome | 0 |
235 | Hypoparathyroidism | 0 |
283 | Acquired pure red cell aplasia | 0 |
296 | Biliary atresia | 0 |
299 | Cystic fibrosis | 0 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT03723447 (ClinicalTrials.gov) | October 23, 2018 | 26/10/2018 | Intraoperative TAP Block With Bupivacaine/Dexamethasone Against Liposomal Bupivacaine (Exparel®) | A Prospective Randomized Trial of Transversus Abdominis Plane (TAP) INtraoperative Block With Bupivacaine/Dexamethasone aGainst Liposomal Bupivacaine (Exparel®): the TINGLE Trial | Pain, Postoperative;Crohn Disease;Inflammatory Bowel Diseases;Colorectal Cancer;Gastrointestinal Cancer;Gastrointestinal Disease;Digestive System Disease;Pain;Pain, Neuropathic;Intestinal Disease | Drug: Liposomal bupivacaine;Drug: Bupivacaine/epinephrine/dexamethasone | Cedars-Sinai Medical Center | NULL | Active, not recruiting | 18 Years | 90 Years | All | 100 | Phase 4 | United States |